We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 19% in a year while the S&P 500 rose 11%.
“This strong underlying performance allows us to maintain our core growth (1) and margin-expansion outlook for the full year”
| Outperforming | Up 51% in 6 months vs the S&P's 0% |
| Its score | Up:Excellent or better for 37 days in a row |
| Latest filing | 10-Q, Sep 1 |
After its last 4 reports it closed +4.5% on average, higher 3 of 4 times.
Excellentfor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
A is #3 of 15 by Quality Score among Laboratory Analytical Instruments.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Net income over four quarters: A $1.44B, ILMN $825M, BIO $222M, BRKR -$71.2M.
Reports Mon Nov 23, after the close (in 16 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
A's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $7.49B to $7.51B |
Sales grew 5.4% a year over 5 years, fiscal 2020 to 2025.
Pays $1.02 a share a year.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 26, 2026 | +2.8% | +1.7% | -2.4% |
| May 27, 2026 | +14.8% | +16.9% | +18.6% |
| Feb 25, 2026 | -2.3% | -3.0% | -3.4% |
Sales grew in five of the last seven years, to $6.9B in 2025. It made a profit in each of the six years.
One insider sold $313K across 2 filings in the last 6 months. No open-market buys on record. The newest:
7 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: A is 0.2% of VIG, under 0.1% of DGRO, and under 0.1% of SPYI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Jul 31, 2026.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
A scores 15 today, which Breakaway calls Excellent. It is #3 of 15 in Laboratory Analytical Instruments by Quality Score, with 5 of 14 chart checks firing. Up 19% in a year while the S&P 500 rose 11%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
A scores 15 today, which Breakaway calls Excellent (15 to 19). That is #3 of 15 in Laboratory Analytical Instruments by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind A's 15.
One insider sold $313K across 2 filings in the last 6 months. No open-market buys on record. The newest is Mikael Dolsten, Director, who sold $96K on Sep 4. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.